Uveitis (Ophthalmology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis – Drugs In Development, 2021, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 8, 8, 1, 1, 47 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Aciont Inc

Active Biotech AB

Aerie Pharmaceuticals Inc

Afecta Pharmaceuticals Inc

Affibody AB

Akari Therapeutics Plc

Aldeyra Therapeutics Inc

Alpine Immune Sciences Inc

Alvotech ehf

Apidel SA

Apitope International NV

Avirmax Inc

BioMarck Pharmaceuticals Ltd

Bonac Corp

Cellivery Therapeutics Inc

Chugai Pharmaceutical Co Ltd

Dobecure SL

E&B Technologies LLC

Elasmogen Ltd

Enzo Biochem Inc

EyeGate Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

HanAll Biopharma Co Ltd

Hengenix Biotech Inc

iCELL Biotechnology Co Ltd

Idogen AB

InSight Biopharmaceuticals Ltd

Juvenescence UK Ltd

Kodiak Sciences Inc

Kriya Therapeutics Inc

Kubota Vision Inc

Kv1.3 Therapeutics

MetrioPharm AG

Mitotech SA

Naegis Pharmaceuticals Inc

NeuClone Pty Ltd

Novaliq GmbH

Novartis AG

Oculis SA

OKYO Pharma Ltd

OncoNOx ApS

ONL Therapeutics Inc

Orchid Pharma Ltd

OSE Immunotherapeutics

Oxular Ltd

Palatin Technologies Inc

Panag Pharma Inc

Pharmapraxis

Re-Pharm Ltd

Reven Pharmaceuticals Inc

Revolo Biotherapeutics Ltd

RiniSight Inc

Ripple therapeutics Corp

Santen Pharmaceutical Co Ltd

SFA Therapeutics LLC

Skye Bioscience Inc

Sol-Gel Technologies Ltd

Sparrow Pharmaceuticals Inc

Tarsius Pharma Ltd

Tianjin Pharmaceuticals Group Co Ltd

Valitor Inc

Vyome Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Uveitis - Overview

Uveitis - Therapeutics Development

Uveitis - Therapeutics Assessment

Uveitis - Companies Involved in Therapeutics Development

Uveitis - Drug Profiles

Uveitis - Dormant Projects

Uveitis - Discontinued Products

Uveitis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Uveitis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Uveitis – Pipeline by Aciont Inc, 2021

Uveitis – Pipeline by Active Biotech AB, 2021

Uveitis – Pipeline by Aerie Pharmaceuticals Inc, 2021

Uveitis – Pipeline by Afecta Pharmaceuticals Inc, 2021

Uveitis – Pipeline by Affibody AB, 2021

Uveitis – Pipeline by Akari Therapeutics Plc, 2021

Uveitis – Pipeline by Aldeyra Therapeutics Inc, 2021

Uveitis – Pipeline by Alpine Immune Sciences Inc, 2021

Uveitis – Pipeline by Alvotech ehf, 2021

Uveitis – Pipeline by Apidel SA, 2021

Uveitis – Pipeline by Apitope International NV, 2021

Uveitis – Pipeline by Avirmax Inc, 2021

Uveitis – Pipeline by BioMarck Pharmaceuticals Ltd, 2021

Uveitis – Pipeline by Bonac Corp, 2021

Uveitis – Pipeline by Cellivery Therapeutics Inc, 2021

Uveitis – Pipeline by Chugai Pharmaceutical Co Ltd, 2021

Uveitis – Pipeline by Dobecure SL, 2021

Uveitis – Pipeline by E&B Technologies LLC, 2021

Uveitis – Pipeline by Elasmogen Ltd, 2021

Uveitis – Pipeline by Enzo Biochem Inc, 2021

Uveitis – Pipeline by EyeGate Pharmaceuticals Inc, 2021

Uveitis – Pipeline by EyePoint Pharmaceuticals Inc, 2021

Uveitis – Pipeline by Eyevensys SAS, 2021

Uveitis – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Uveitis – Pipeline by HanAll Biopharma Co Ltd, 2021

Uveitis – Pipeline by Hengenix Biotech Inc, 2021

Uveitis – Pipeline by iCELL Biotechnology Co Ltd, 2021

Uveitis – Pipeline by Idogen AB, 2021

Uveitis – Pipeline by InSight Biopharmaceuticals Ltd, 2021

Uveitis – Pipeline by Juvenescence UK Ltd, 2021

Uveitis – Pipeline by Kodiak Sciences Inc, 2021

Uveitis – Pipeline by Kriya Therapeutics Inc, 2021

Uveitis – Pipeline by Kubota Vision Inc, 2021

Uveitis – Pipeline by Kv1.3 Therapeutics, 2021

Uveitis – Pipeline by MetrioPharm AG, 2021

Uveitis – Pipeline by Mitotech SA, 2021

Uveitis – Pipeline by Naegis Pharmaceuticals Inc, 2021

Uveitis – Pipeline by NeuClone Pty Ltd, 2021

Uveitis – Pipeline by Novaliq GmbH, 2021

Uveitis – Pipeline by Novartis AG, 2021

Uveitis – Pipeline by Oculis SA, 2021

Uveitis – Pipeline by OKYO Pharma Ltd, 2021

Uveitis – Pipeline by OncoNOx ApS, 2021

Uveitis – Pipeline by ONL Therapeutics Inc, 2021

Uveitis – Pipeline by Orchid Pharma Ltd, 2021

Uveitis – Pipeline by OSE Immunotherapeutics, 2021

Uveitis – Pipeline by Oxular Ltd, 2021

Uveitis – Pipeline by Palatin Technologies Inc, 2021

Uveitis – Pipeline by Panag Pharma Inc, 2021

Uveitis – Pipeline by Pharmapraxis, 2021

Uveitis – Pipeline by Re-Pharm Ltd, 2021

Uveitis – Pipeline by Reven Pharmaceuticals Inc, 2021

Uveitis – Pipeline by Revolo Biotherapeutics Ltd, 2021

Uveitis – Pipeline by RiniSight Inc, 2021

Uveitis – Pipeline by Ripple therapeutics Corp, 2021

Uveitis – Pipeline by Santen Pharmaceutical Co Ltd, 2021

Uveitis – Pipeline by SFA Therapeutics LLC, 2021

Uveitis – Pipeline by Skye Bioscience Inc, 2021

Uveitis – Pipeline by Sol-Gel Technologies Ltd, 2021

Uveitis – Pipeline by Sparrow Pharmaceuticals Inc, 2021

Uveitis – Pipeline by Tarsius Pharma Ltd, 2021

Uveitis – Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2021

Uveitis – Pipeline by Valitor Inc, 2021

Uveitis – Pipeline by Vyome Therapeutics Inc, 2021

Uveitis – Dormant Projects, 2021

Uveitis – Dormant Projects, 2021 (Contd..1)

Uveitis – Dormant Projects, 2021 (Contd..2)

Uveitis – Dormant Projects, 2021 (Contd..3)

Uveitis – Dormant Projects, 2021 (Contd..4)

Uveitis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Uveitis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports